首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Nonsteroidal antiinflammatory agents-part 2 antiinflammatory, analgesic and antipyretic activity of some substituted 3-pyrazolin-5-ones and 1,2,4,5,6,7-3H-hexahydroindazol-3-ones.
【24h】

Nonsteroidal antiinflammatory agents-part 2 antiinflammatory, analgesic and antipyretic activity of some substituted 3-pyrazolin-5-ones and 1,2,4,5,6,7-3H-hexahydroindazol-3-ones.

机译:非甾体类抗炎药-第2部分对某些取代的3-吡唑啉-5-酮和1,2,4,5,6,7-3H-六氢吲哚-3-酮具有抗炎,镇痛和解热活性。

获取原文
获取原文并翻译 | 示例
           

摘要

As a part of a research project on the synthesis of a number of substituted 1-(pyrimidin-2-yl)-3-pyrazolin-5-ones and 2-(pyrimidin-2-yl)hexahydroindazol-3-ones and as a result of the interesting antiinflammatory, analgesic and antipyretic activities recorded for some of these compounds, some new 3-pyrazolin-5-ones and hexahydroindazol-3-ones linked to substituted imidazolyl, pyrimidyl and tetrahydroquinazolinyl moieties were prepared and evaluated for such activity (). A structure-activity relationship (SAR) comparative study indicated that some compounds from 3-pyrazolin-5-one (2, 6-8, 10) and indazolone (18, 20, 24, 27, 29) series exhibited pronounced antiinflammatory, analgesic and antipyretic activities relative to indomethacin. Most of these compounds were found to be nearly equipotent in the antiinflammatory screen (ED(50)=16.8-19.9 mg/kg) whereas the lead compound, 2-indazolyl-4-pyrimidineacetic acid 24 (), was found to be the most potent among this series (ED(50)=9.9 mg/kg). Additionally, the most active compounds were shown to have a large safety margin (ALD(50)=3.0 g/kg, po) and devoid of ulcerogenic potentialities when administered orally at a dose of 300 mg/kg.
机译:作为合成许多取代的1-(嘧啶-2-基)-3-吡唑啉-5-酮和2-(嘧啶-2-基)六氢吲唑-3-酮的研究项目的一部分,这些化合物中记录的有趣的抗炎,镇痛和解热活性的结果,制备了一些与取代的咪唑基,嘧啶基和四氢喹唑啉基部分连接的新的3-吡唑啉-5-酮和六氢吲唑-3-酮,并对其活性进行了评估() 。结构-活性关系(SAR)比较研究表明,3-吡唑啉-5-酮(2,6-8,10)和吲唑酮(18,20,24,27,29)系列的某些化合物表现出明显的抗炎,镇痛作用和消炎痛相关的解热活性。这些化合物中的大多数在抗炎筛选中被认为是等效的(ED(50)= 16.8-19.9 mg / kg),而主要化合物2-吲唑基-4-嘧啶乙酸24()被发现是最多的。此系列中的强效(ED(50)= 9.9 mg / kg)。此外,当以300 mg / kg的剂量口服时,活性最高的化合物显示出较大的安全系数(ALD(50)= 3.0 g / kg,po),并且没有致溃疡的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号